Glaukos (NYSE:GKOS – Get Free Report) and Anteris Technologies Global (NASDAQ:AVR – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
Profitability
This table compares Glaukos and Anteris Technologies Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Glaukos | -36.99% | -7.00% | -5.38% |
| Anteris Technologies Global | -4,921.27% | -536.04% | -267.57% |
Risk and Volatility
Glaukos has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Glaukos | 2 | 1 | 12 | 1 | 2.75 |
| Anteris Technologies Global | 1 | 0 | 3 | 0 | 2.50 |
Glaukos currently has a consensus target price of $133.69, indicating a potential upside of 18.64%. Anteris Technologies Global has a consensus target price of $15.33, indicating a potential upside of 178.79%. Given Anteris Technologies Global’s higher possible upside, analysts plainly believe Anteris Technologies Global is more favorable than Glaukos.
Valuation and Earnings
This table compares Glaukos and Anteris Technologies Global”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Glaukos | $507.44 million | 12.90 | -$187.69 million | ($3.26) | -34.57 |
| Anteris Technologies Global | $1.91 million | 279.98 | -$94.14 million | ($2.56) | -2.15 |
Anteris Technologies Global has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
99.0% of Glaukos shares are owned by institutional investors. 5.8% of Glaukos shares are owned by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Glaukos beats Anteris Technologies Global on 9 of the 15 factors compared between the two stocks.
About Glaukos
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
